A case study on how Recipharm developed a suitable analysis method for Lobsor Pharmaceutical's advanced Parkinson’s disease treatment, Lecigon® intestinal gel.
Prezes Agencji nie rekomenduje objęcie refundacją produktu leczniczego Lecigon (lewodopa + karbidopa + entakapon) w ramach programu lekowego B.90. „Leczenie zaburzeń motorycznych w przebiegu ...
Group adjusted constant-currency (cc) revenues rise by 4% and adjusted cc EBITDA improves by 5% to a record €245 million in first quarter of 2025 Specialty adjusted cc revenues climb by 22%, driven by ...
Group sales increase by 9% to € 4.059 billion; adjusted cc EBITDA rises by 11% to € 886 million; adjusted cc EBITDA margin up to 21.8%; further sales and profits growth targeted in 2025 In Europe, ...
STADA, a leading healthcare and pharmaceutical company in Consumer Healthcare, Generics and Specialty pharmaceuticals, continued its profitable growth journey in 2024. STADA again outperformed market ...
Two new medicines have been accepted for use on the NHS in Scotland (Julien Behal/PA) A treatment for a rare type of cancer has been accepted for use on the NHS in Scotland. The Scottish Medicines ...
Specialty sales that advanced by 14% to €417.3 million – accounting for 21% of total group revenues in the first half of 2024 – were driven both by STADA’s expanded portfolio, which now comprises ...
Group revenues with above-market growth of 9% take half-year turnover over €2 billion, resulting in double-digit profit increase Specialty was STADA’s fastest-growing and highest-margin segment in the ...
STOCKHOLM, April 9, 2024 /PRNewswire/ -- Tridentify are delighted to announce that Intrance Medical Systems Inc. now have signed a LOI purchase commitment of $ 300 000. Their Tridentify safeguarding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results